- Price outlook for Injective (INJ) as Republic expands RWA integration with Injective.
- The INJ token trades near $13.38 after falling from $16 highs amid a broader crypto sell-off.
- ETF expectations, tokenization growth and other catalysts could support INJ bulls.
Injective is trading around $13.38 on Thursday evening, down roughly 3% over the past 24 hours and more than 12% over the past week. With this pullback, can Injective’s integration with Republic help push INJ back toward $20?
Over the past week Injective has slipped from $16 peaks, pressure largely driven by market-wide selling.
That decline comes despite notable ecosystem milestones for the finance-focused Layer 1 blockchain.
Now, with Republic—a leading tokenized investment platform—joining in, bulls may have reason to target higher prices if the broader market turns positive.
Injective integrates with Republic
Even as the crypto market corrects, platform development continues.
Integrations are a key part of that work, and Injective has advanced this effort through an official integration with Republic.
The platforms announced the partnership on August 21, aiming to bring Injective’s Layer 1 ecosystem into Republic’s on-chain investment infrastructure.
Specifically, the integration intends to enable Injective-based projects to raise capital via Republic’s Launchpad, use the Republic Wallet for asset management, and leverage Republic’s validation support.
Why this integration matters
Republic and Injective had already collaborated with Republic acting as an INJ validator.
Importantly, this new integration represents a further step toward expanding private markets on-chain.
“With 3 million+ community members across 150+ countries and a portfolio that includes 27 unicorns such as SpaceX, Robinhood, Carta and Dapper Labs, Republic’s integration with Injective marks a pivotal moment for bridging traditional financing with on-chain innovation,” Injective said.
INJ price outlook: Can bulls reclaim $30?
Technically, INJ looks vulnerable in the short term, with indicators like RSI and MACD favoring the downside.
Trading near $13 places Injective closer to the $6.90 lows seen in April 2025 than to the $34 highs from December 2024.
Market-wide selling that has affected Bitcoin and altcoins has not helped the bulls.
Injective price chart from CoinMarketCap
However, if sentiment improves, a breakout to $20 could set bulls up to target $30.
Beyond the Republic integration, other meaningful upside drivers include broader institutional interest and growing demand tied to tokenization and real-world assets.
Injective’s push to lead with new financial primitives designed to expand its DeFi capabilities—alongside emerging markets such as Nvidia GPU derivatives—adds to the bullish narrative.
Another potential tailwind for INJ is ETF-related speculation: filings, possible approvals and associated accumulation would be important contributors.
That said, bulls need to hold above $13—and ideally keep above $10—to avoid ceding greater control to the bears.